Heather Wakelee

Medical oncologist, Thoracic specialist

Associate Professor of Medicine (Oncology) at the Stanford University Medical Center

Thoracic Cancer Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: Stanford University Medical Center (2003) CA

Residency: Stanford University Medical Center (1999) CA

Board Certification: Medical Oncology, American Board of Internal Medicine (2003)

Internship: Stanford University Medical Center (1997) CA

Medical Education: Johns Hopkins University School of Medicine (1996) MD

M. D., Johns Hopkins University, Medicine (1996)

A.B., Princeton University, Molecular Biology (1992)

Honors & Awards

Teaching Award, Stanford University Division of Oncology (2007, 2008, 2009, 2011)

Alpha Omega Alpha, Johns Hopkins University (06/1996)

Merit Award, American Society of Clinical Oncology (05/2003)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients Eastern Cooperative Oncology Group Study E2501
Wakelee, H. A., Lee, J.-W., Hanna, N. H., Traynor, A. M., Carbone, D. P., & Schiller, J. H. (2012). A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients Eastern Cooperative Oncology Group Study E2501. JOURNAL OF THORACIC ONCOLOGY, 7(10), 1574-1582.

Lung cancer incidence in never smokers
Wakelee, H. A., Chang, E. T., Gomez, S. L., Keegan, T. H., Feskanich, D., & West, D. W. (2007). Lung cancer incidence in never smokers. JOURNAL OF CLINICAL ONCOLOGY, 25(5), 472-478.

A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., & Wakelee, H. A. (2013). A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. CLINICAL LUNG CANCER, 14(5), 592-595.

Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report
Padda, S. K., Chhatwani, L., Zhou, L., Jacobs, C. D., Lopez-Anaya, A., & Wakelee, H. A. (2013). Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report. ANTI-CANCER DRUGS, 24(7), 731-735.

A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
Riess, J. W., Nagpal, S., Neal, J. W., & Wake, H. A. (2013). A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(4), 389-394.

A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Journal of thoracic oncology , 8(2), e17-8.

Aflibercept in lung cancer
Neal, J. W., & Wakelee, H. A. (2013). Aflibercept in lung cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 13(1), 115-120.

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer
Clement-Duchene, C., Natale, R. B., Jahan, T., Krupitskaya, Y., Osarogiagbon, R., & Wakelee, H. A. (2012). A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. LUNG CANCER, 78(1), 57-62.

Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors
Trakul, N., Chang, C. N., Harris, J., Chapman, C., Rao, A., & Diehn, M. (2012). Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(1), 231-237.

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. Ra., Colevas, A. D., & Wakelee, H. A. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. BRITISH JOURNAL OF CANCER, 107(4), 604-611.

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
Das, M., Riess, J. W., Frankel, P., Schwartz, E., Bennis, R., & Bruce, R. H. (2012). ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung cancer , 77(2), 421-426.

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab
Wakelee, H. A., DAHLBERG, S. E., Brahmer, J. R., Schiller, J. H., Perry, M. C., & Johnson, D. H. (2012). Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. LUNG CANCER, 76(3), 410-415.

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
Riess, J. W., & Wakelee, H. A. (2012). Metastatic non-small cell lung cancer management: novel targets and recent clinical advances. Clinical advances in hematology & oncology : H&O, 10(4), 226-234.

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., & Wakelee, H. A. (2012). A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(4), 1013-1020.

A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Wakelee, H. A., Middleton, G., Dunlop, D., Ramlau, R., Leighl, N., & Jacobs, C. D. (2012). A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(3), 815-824.

Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer
Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., & Wakelee, H. A. (2012). Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. CANCER INVESTIGATION, 30(3), 231-235.

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
Rodon, J., Jacobs, C. D., Chu, Q., Rowinsky, E. K., Lopez-Anaya, A., & Wakelee, H. A. (2012). A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC). CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(3), 825-834.

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer
Wakelee, H. A., Takimoto, C. H., Lopez-Anaya, A., Chu, Q., Middleton, G., & Rodon, J. (2012). The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(2), 563-571.

Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer
Lee, P., Bazan, J. G., Lavori, P. W., Weerasuriya, D. K., Quon, A., & Loo, B. W. (2012). Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 13(1), 52-58.

XL647-A Multitargeted Tyrosine Kinase Inhibitor Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib
Pietanza, M. C., Lynch, T. J., Lara, P. N., Cho, J., Yanagihara, R. H., & Miller, V. A. (2012). XL647-A Multitargeted Tyrosine Kinase Inhibitor Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib. JOURNAL OF THORACIC ONCOLOGY, 7(1), 219-226.

Current Management of Small Cell Lung Cancer
Neal, J. W., Gubens, M. A., & Wakelee, H. A. (2011). Current Management of Small Cell Lung Cancer. CLINICS IN CHEST MEDICINE, 32(4), 853-?.

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., & Giaccone, G. (2011). American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 2121-2127.

Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer
Kozak, M. M., Murphy, J. D., Schipper, M. L., Donington, J. S., Zhou, L., & Loo, B. W. (2011). Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 6(5), 920-926.

Survival following Non-Small Cell Lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic White Women Who Have Never Smoked
Gomez, S. L., Chang, E. T., Shema, S. J., Fish, K., Sison, J. D., & Wakelee, H. A. (2011). Survival following Non-Small Cell Lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic White Women Who Have Never Smoked. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 20(3), 545-554.

A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., & Wakelee, H. A. (2010). A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 5(11), 1821-1825.

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules
Advani, R. H., Hurwitz, H. I., Gordon, M. S., Ebbinghaus, S. W., Mendelson, D. S., & Adelman, D. C. (2010). Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. CLINICAL CANCER RESEARCH, 16(7), 2167-2175.

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., & Tolcher, A. W. (2010). Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. ANNALS OF ONCOLOGY, 21(2), 376-381.

A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A., & Wakelee, H. (2009). A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 4(9), S674-S674.

Uncovering Disparities in Survival after Non-Small-Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California
Chang, E. T., Shema, S. J., Wakelee, H. A., Clarke, C. A., & Gomez, S. L. (2009). Uncovering Disparities in Survival after Non-Small-Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 18(8), 2248-2255.

Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer
Krupitskaya, Y., & Wakelee, H. A. (2009). Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 10(6), 597-605.

A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC)
Krupitskaya, Y., Ganjoo, K., Lavori, P. W., Kumar, A., Clement-Duchene, C., & Wakelee, H. A. (2009). A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 27(15).

Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial
West, H. L., Wakelee, H. A., Perry, M. C., Belt, R. J., Chen, R., & Obasaju, C. (2009). Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. ANNALS OF ONCOLOGY, 20(5), 850-856.

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy
Krupitskaya, Y., Eslamy, H. K., Nguyen, D. D., Kumar, A., & Wakelee, H. A. (2009). Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy. JOURNAL OF THORACIC ONCOLOGY, 4(3), 429-431.

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy
Hsu, J. Y., & Wakelee, H. A. (2009). Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy. BIODRUGS, 23(5), 289-304.

Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non-Small-Cell Lung Cancer
Wakelee, H., Kernstine, K., Vokes, E., Schiller, J., Baas, P., & Putnam Joe "Bill". (2008). Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 9(6), 346-351.

Adjuvant chemotherapy for resected non-small cell lung cancer.
Wakelee, H., & Chhatwani, L. (2008). Adjuvant chemotherapy for resected non-small cell lung cancer. Seminars in thoracic and cardiovascular surgery, 20(3), 198-203.

Sex differences in lung-cancer susceptibility: a smoke screen?
Wakelee, H. A., Gomez, S. L., & Chang, E. T. (2008). Sex differences in lung-cancer susceptibility: a smoke screen?. LANCET ONCOLOGY, 9(7), 609-610.

Summary statement - Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy
Lynch, T. J., Blumenschein, G. R., Engelman, J. A., Espinoza-Delgado, I., Govindan, R., & Weitzman, A. (2008). Summary statement - Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. JOURNAL OF THORACIC ONCOLOGY, 3(6), S107-S112.

Antibodies to vascular endothelial growth factor in non-small cell lung cancer
Wakelee, H. (2008). Antibodies to vascular endothelial growth factor in non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 3(6), S113-S118.

Complications of ablative therapies in lung cancer
Padda, S., Kothary, N., Donington, J., Cannon, W., Loo, B. W., & Wakelee, H. (2008). Complications of ablative therapies in lung cancer. CLINICAL LUNG CANCER, 9(2), 122-126.

Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?
Langer, C. J., Wakelee, H., Schiller, J., Choy, H., Shepherd, F., & Gandara, D. R. (2008). Cooperative group portfolio in locally advanced non-small-cell lung cancer: Are we making progress?. CLINICAL LUNG CANCER, 9(2), 85-91.

Diagnosis in oncology - Lung cancer presenting with amegakaryocytic thrombocytopenia
Witteles, W. H., Schrier, S. L., & Wakelee, H. A. (2008). Diagnosis in oncology - Lung cancer presenting with amegakaryocytic thrombocytopenia. JOURNAL OF CLINICAL ONCOLOGY, 26(7), 1171-1174.

Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer
Wakelee, H., Langer, C., Vokes, E., Schiller, J., Baas, P., & Gandara, D. R. (2008). Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer. CLINICAL LUNG CANCER, 9(1), 9-15.

Metabolic tumor burden predicts for disease progression and death in lung cancer
Lee, P., Weerasuriya, D. K., Lavori, P. W., Quon, A., Hara, W., & Loo, B. W. (2007). Metabolic tumor burden predicts for disease progression and death in lung cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(2), 328-333.

Adjuvant chemotherapy of stage I non-small cell lung cancer in North America
Gandara, D. R., Wakelee, H., Calhoun, R., & Jablons, D. (2007). Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. JOURNAL OF THORACIC ONCOLOGY, 2(7), S125-S127.

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe, E., & Wakelee, H. (2007). Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Current treatment options in oncology, 8(1), 15-27.

Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease
Wakelee, H., Dubey, S., & Gandara, D. (2007). Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease. ONCOLOGIST, 12(3), 331-337.

Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors
Le, Q.-T., Loo, B. W., Ho, A., Cotrutz, C., Koong, A. C., & Donington, J. (2006). Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. JOURNAL OF THORACIC ONCOLOGY, 1(8), 802-809.

A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma
Roy, M. S., Le, Q.-T., Donington, J. S., & Wakelee, H. A. (2006). A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma. CLINICAL LUNG CANCER, 8(2), 146-148.

Lung cancer in women: Exploring sex differences in susceptibility, biology, and therapeutic response
Donington, J. S., Le, Q.-T., & Wakelee, H. A. (2006). Lung cancer in women: Exploring sex differences in susceptibility, biology, and therapeutic response. CLINICAL LUNG CANCER, 8(1), 22-29.

Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: Implications for the new intergroup trial
Wakelee, H. A., Schiller, J. H., & Gandara, D. R. (2006). Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: Implications for the new intergroup trial. CLINICAL LUNG CANCER, 8(1), 18-21.

Sunitinib: A newly approved small-molecule inhibitor of angiogenesis
Cabebe, E., & Wakelee, H. (2006). Sunitinib: A newly approved small-molecule inhibitor of angiogenesis. DRUGS OF TODAY, 42(6), 387-398.

Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
Wakelee, H. A., Wang, W., Schiller, J. H., Langer, C. J., Sandler, A. B., & Johnson, D. H. (2006). Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. JOURNAL OF THORACIC ONCOLOGY, 1(5), 441-446.

Changes in the natural history of nonsmall cell lung cancer (NSCLC) - Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990
Wakelee, H. A., Bernardo, P., Johnson, D. H., & Schiller, J. H. (2006). Changes in the natural history of nonsmall cell lung cancer (NSCLC) - Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. CANCER, 106(10), 2208-2217.

An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers
Le, Q. T., Chen, E., Salim, A., Cao, H. B., Kong, C. S., & Giaccia, A. J. (2006). An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. CLINICAL CANCER RESEARCH, 12(5), 1507-1514.

Second- and third-line treatments in non-small cell lung cancer.
Kumar, A., & Wakelee, H. (2006). Second- and third-line treatments in non-small cell lung cancer. Current treatment options in oncology, 7(1), 37-49.

Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: Novel agents with potential in lung cancer
Wakelee, H. A., & Schiller, J. H. (2005). Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: Novel agents with potential in lung cancer. CLINICAL LUNG CANCER, 7, S31-S38.

Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors
Wakelee, H. A., & Sikic, B. I. (2005). Activity of novel cytotoxic agents in lung cancer: Epothilones and topoisomerase I inhibitors. CLINICAL LUNG CANCER, 7, S6-S12.

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., & Sikic, B. I. (2005). Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(24), 5613-5619.

Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590
Wakelee, H. A., Stephenson, P., Keller, S. M., Wagner, H., Herskovic, A., & Johnson, D. H. (2005). Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. LUNG CANCER, 48(3), 389-397.

A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer
Wakelee, H., & Fisher, G. A. (2005). A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. INVESTIGATIONAL NEW DRUGS, 23(3), 241-242.

Docetaxel in advanced non-small cell lung cancer
Wakelee, H., Ramalingam, S., & Belani, C. P. (2005). Docetaxel in advanced non-small cell lung cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 5(1), 13-24.

Optimizing first-line treatment options for patients with advanced NSCLC
Wakelee, H., & Belani, C. P. (2005). Optimizing first-line treatment options for patients with advanced NSCLC. ONCOLOGIST, 10, 1-10.

Novel approaches for the treatment of small cell lung cancer
Wakelee, H., & Kelly, K. (2004). Novel approaches for the treatment of small cell lung cancer. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 18(2), 499-?.

Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines
HAWS, C. M., Nepomuceno, I. B., Krouse, M. E., Wakelee, H., Law, T., & Wine, J. J. (1996). Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 270(5), C1544-C1555.